Therapeutic Solutions International (Therapeutic Solutions International) Forward Dividend Yield % : 0.00% (As of May. 26, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Therapeutic Solutions International Forward Dividend Yield %?

As of today (2024-05-26), the Forward Annual Dividend Yield of Therapeutic Solutions International is 0.00%.

As of today (2024-05-26), the Trailing Annual Dividend Yield of Therapeutic Solutions International is 0.00%.

TSOI's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful Forward Dividend Yield % only.

Therapeutic Solutions International's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Therapeutic Solutions International's Forward Dividend Yield %

For the Biotechnology subindustry, Therapeutic Solutions International's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Therapeutic Solutions International's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Therapeutic Solutions International's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Therapeutic Solutions International's Forward Dividend Yield % falls into.

Therapeutic Solutions International Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Therapeutic Solutions International (OTCPK:TSOI) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Therapeutic Solutions International Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Therapeutic Solutions International's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Therapeutic Solutions International (Therapeutic Solutions International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Therapeutic Solutions International Inc (OTCPK:TSOI) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

701 Wild Rose Lane, Elk City, ID, USA, 83525

Website

https://www.therapeuticsolutionsint.com

Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).

Executives

Thomas Ichim	director	211 E. OSBORN RD, PHOENIX AZ 85012
Gerry B Berg	officer: CFO	1658 AVENIDA LA POSTA, ENCINITAS CA 92024
Timothy G Dixon	director, officer: Chairman, President, CEO	4093 OCEANSIDE BLVD., SUITE B, OCEANSIDE CA 92056
Barry Glassman	officer: VP, Training & Education	2051 ELBOW LANE, ALLENTOWN PA 18103
James P Boyd	director, 10 percent owner	PO BOX 2145, RANCHO SANTA FE CA 92067